Helen Fedor

5.9k total citations · 1 hit paper
41 papers, 2.4k citations indexed

About

Helen Fedor is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Cancer Research. According to data from OpenAlex, Helen Fedor has authored 41 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Pulmonary and Respiratory Medicine, 18 papers in Molecular Biology and 11 papers in Cancer Research. Recurrent topics in Helen Fedor's work include Prostate Cancer Treatment and Research (25 papers), Prostate Cancer Diagnosis and Treatment (12 papers) and Molecular Biology Techniques and Applications (10 papers). Helen Fedor is often cited by papers focused on Prostate Cancer Treatment and Research (25 papers), Prostate Cancer Diagnosis and Treatment (12 papers) and Molecular Biology Techniques and Applications (10 papers). Helen Fedor collaborates with scholars based in United States, Canada and Brazil. Helen Fedor's co-authors include Angelo M. De Marzo, Justin C. McArthur, Jonathan D. Glass, Steve Wesselingh, William B. Isaacs, Jessica Hicks, Michael C. Haffner, Tamara L. Lotan, Alan W. Partin and Karen S. Sfanos and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Helen Fedor

41 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Immunocytochemical quantitation of human immunodeficiency virus in the brain: Correlations with dementia

1995 561 citations Jonathan D. Glass, Helen Fedor et al. Annals of Neurology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Helen Fedor United States	22	1.2k	756	589	520	452	41	2.4k
Shalini S. Yadav United States	21	481 0.4×	840 1.1×	388 0.7×	275 0.5×	940 2.1×	53	2.4k
Raffaella Soldi United States	26	253 0.2×	1.8k 2.4×	396 0.7×	198 0.4×	454 1.0×	53	2.8k
Yaoyu E. Wang United States	21	156 0.1×	854 1.1×	284 0.5×	351 0.7×	368 0.8×	35	1.6k
Josep Castellví Spain	33	548 0.5×	1.7k 2.3×	838 1.4×	188 0.4×	1.0k 2.2×	109	3.6k
Makoto Kubo Japan	30	251 0.2×	1.3k 1.7×	571 1.0×	97 0.2×	918 2.0×	126	3.0k
Winson W. Tang United States	23	285 0.2×	1.1k 1.5×	98 0.2×	314 0.6×	535 1.2×	31	2.8k
Xuejun Fan United States	28	178 0.2×	906 1.2×	172 0.3×	117 0.2×	695 1.5×	68	2.9k
Monika Pruenster Germany	27	196 0.2×	628 0.8×	98 0.2×	267 0.5×	683 1.5×	35	2.4k
Hua Huang China	29	446 0.4×	1.3k 1.7×	658 1.1×	80 0.2×	662 1.5×	144	3.3k
Karl‐Henning Kalland Norway	34	288 0.2×	1.5k 2.0×	520 0.9×	167 0.3×	658 1.5×	81	2.5k

Countries citing papers authored by Helen Fedor

Since Specialization

Citations

This map shows the geographic impact of Helen Fedor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Helen Fedor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Helen Fedor more than expected).

Fields of papers citing papers by Helen Fedor

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Helen Fedor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Helen Fedor. The network helps show where Helen Fedor may publish in the future.

Co-authorship network of co-authors of Helen Fedor

This figure shows the co-authorship network connecting the top 25 collaborators of Helen Fedor. A scholar is included among the top collaborators of Helen Fedor based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Helen Fedor. Helen Fedor is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Guedes, Liana B., Carlos L. Morais, Helen Fedor, et al.. (2018). Effect of Preanalytic Variables on an Automated PTEN Immunohistochemistry Assay for Prostate Cancer. Archives of Pathology & Laboratory Medicine. 143(3). 338–348. 5 indexed citations

Lotan, Tamara L., Alba Torres, Miao Zhang, et al.. (2017). Somatic molecular subtyping of prostate tumors from HOXB13 G84E carriers. Oncotarget. 8(14). 22772–22782. 9 indexed citations

Morais, Carlos L., Filipe L.F. Carvalho, Sarah B. Peskoe, et al.. (2016). In prostate cancer needle biopsies, detections of PTEN loss by fluorescence in situ hybridization (FISH) and by immunohistochemistry (IHC) are concordant and show consistent association with upgrading. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 468(5). 607–617. 27 indexed citations

Trock, Bruce J., Helen Fedor, Bora Gürel, et al.. (2016). PTEN loss and chromosome 8 alterations in Gleason grade 3 prostate cancer cores predicts the presence of un-sampled grade 4 tumor: implications for active surveillance. Modern Pathology. 29(7). 764–771. 46 indexed citations

Faraj, Sheila F., Stephania Martins Bezerra, Kasra Yousefi, et al.. (2016). Clinical Validation of the 2005 ISUP Gleason Grading System in a Cohort of Intermediate and High Risk Men Undergoing Radical Prostatectomy. PLoS ONE. 11(1). e0146189–e0146189. 11 indexed citations

Ross, Ashley E., Michael H. Johnson, Kasra Yousefi, et al.. (2015). Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men. European Urology. 69(1). 157–165. 157 indexed citations

Lotan, Tamara L., Filipe L.F. Carvalho, Sarah B. Peskoe, et al.. (2014). PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy. Modern Pathology. 28(1). 128–137. 106 indexed citations

Antonarakis, Emmanuel S., Changxue Lu, Brandon Luber, et al.. (2014). Ar-V7 Splice Variant and Resistance to Enzalutamide and Abiraterone in Men with Metastatic Castration-Resistant Prostate Cancer (Mcrpc): Overall Survival Results. Annals of Oncology. 25. v1–v1. 2 indexed citations

Gümüşkaya, Berrak, Bora Gürel, Helen Fedor, et al.. (2013). Assessing the order of critical alterations in prostate cancer development and progression by IHC: further evidence that PTEN loss occurs subsequent to ERG gene fusion. Prostate Cancer and Prostatic Diseases. 16(2). 209–215. 58 indexed citations

10.

Haffner, Michael C., Timothy L. Mosbruger, David Esopi, et al.. (2013). Tracking the clonal origin of lethal prostate cancer. Journal of Clinical Investigation. 123(11). 4918–4922. 358 indexed citations

11.

Antonarakis, Emmanuel S., Daniel Keizman, Zhe Zhang, et al.. (2012). An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy. Cancer. 118(24). 6063–6071. 85 indexed citations

12.

Armstrong, Andrew J., George J. Netto, Michelle A. Rudek, et al.. (2010). A Pharmacodynamic Study of Rapamycin in Men with Intermediate- to High-Risk Localized Prostate Cancer. Clinical Cancer Research. 16(11). 3057–3066. 62 indexed citations

13.

Kader, A. Karim, Jielin Sun, Helen Fedor, et al.. (2009). POD-02.10: Individual and Cumulative Effect of Prostate Cancer Risk-associated Variants on Clinicopathologic Variables in 5,895 Prostate Cancer Patients. Urology. 74(4). S7–S8. 1 indexed citations

14.

Kader, A. Karim, Jielin Sun, Sarah D. Isaacs, et al.. (2009). Individual and cumulative effect of prostate cancer risk‐associated variants on clinicopathologic variables in 5,895 prostate cancer patients. The Prostate. 69(11). 1195–1205. 76 indexed citations

15.

Dunn, Thomas A., Helen Fedor, William B. Isaacs, Angelo M. De Marzo, & Jun Luo. (2008). Genome‐wide expression analysis of recently processed formalin‐fixed paraffin embedded human prostate tissues. The Prostate. 69(2). 214–218. 16 indexed citations

16.

Sfanos, Karen S., Jurga Sauvageot, Helen Fedor, et al.. (2007). A molecular analysis of prokaryotic and viral DNA sequences in prostate tissue from patients with prostate cancer indicates the presence of multiple and diverse microorganisms. The Prostate. 68(3). 306–320. 174 indexed citations

17.

Faith, Dennis, William B. Isaacs, James Morgan, et al.. (2004). Trefoil factor 3 overexpression in prostatic carcinoma: Prognostic importance using tissue microarrays. The Prostate. 61(3). 215–227. 77 indexed citations

18.

Magi‐Galluzzi, Cristina, J. Kellogg Parsons, Helen Fedor, et al.. (2004). 1543: The Prevalence and Extent of Autopsy Benign Prostatic Hyperplasia (BPH) is Less in South East Asian Men than North American Men. The Journal of Urology. 171(4S). 406–407. 4 indexed citations

19.

Subbiah, Ponni, Peter R. Mouton, Helen Fedor, Justin C. McArthur, & Jonathan D. Glass. (1996). Stereological Analysis of Cerebral Atrophy in Human Immunodeficiency Virus-associated Dementia. Journal of Neuropathology & Experimental Neurology. 55(10). 1032–1037. 24 indexed citations

20.

Glass, Jonathan D., Helen Fedor, Steve Wesselingh, & Justin C. McArthur. (1995). Immunocytochemical quantitation of human immunodeficiency virus in the brain: Correlations with dementia. Annals of Neurology. 38(5). 755–762. 561 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact